Related Experiment Videos

Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis

A R Kitching1, S R Holdsworth, V A Ploplis

  • 1Center for Inflammatory Diseases, Monash University, Department of Medicine, Monash Medical Centre, Victoria, Australia.

Insights

Plasminogen protects kidneys from inflammatory injury. Its deficiency, or that of tissue-type plasminogen activator (tPA), worsens crescentic glomerulonephritis (GN) in mice, highlighting their crucial protective roles.

Area of Science:

  • Nephrology
  • Immunology
  • Molecular Biology

Background:

  • The plasminogen/plasmin system regulates fibrin and matrix protein accumulation, influencing inflammatory disease outcomes.
  • Fibrin and matrix protein deposition are key mediators of glomerular injury and renal impairment in crescentic glomerulonephritis (GN).

Purpose of the Study:

  • To investigate the role of plasminogen and its activators in the pathogenesis of inflammatory glomerular injury.
  • To elucidate the specific contributions of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) in GN.

Main Methods:

  • Induction of crescentic glomerulonephritis (GN) in genetically modified mice lacking plasminogen, tPA, uPA, or uPA receptor.
  • Assessment of functional and histological parameters of glomerular injury and inflammation.

Main Results:

  • Plasminogen deficiency led to severe exacerbation of glomerular injury and renal impairment.
  • Combined deficiency of tPA and uPA, or deficiency of tPA alone, significantly worsened GN.
  • uPA deficiency showed a trend towards reduced macrophage infiltration but did not exacerbate disease.
  • uPA receptor deficiency had no significant effect on GN expression.

Conclusions:

  • Plasminogen is essential for protecting the glomerulus against acute inflammatory injury.
  • Tissue-type plasminogen activator (tPA) is the primary plasminogen activator conferring protection in GN.
  • The plasminogen system, particularly tPA, represents a potential therapeutic target for inflammatory kidney diseases.

Related Concept Videos